The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Failure to Warn: The Week in Drug Safety News

Posted by Brian Overstreet on June 9, 2017

It’s been a very busy week for many of us.  School’s finishing up for the kids here in California (no snow days here!), the annual ACSO conference was in full swing, the Warriors are up 3-0 in the NBA finals, and the media coverage of the Comey hearing has been non-stop.

With everything else going on, we wanted to make sure to draw your attention to some significant drug safety reporting over the past week, as we wouldn’t want to be accused of “failing to warn”!  

Read More

Topics: Drug Safety

How is Evidex Different from Traditional Signal Detection Software?

Posted by Jim Davis on May 26, 2017

When first talking with drug safety departments, we often get asked how our platform is different than systems that they already have in place. The key difference between traditional signal detection software and a drug safety evidence aggregation platform comes down to the types of data they each support, the flexibility in which those data are supported, and the much broader use cases available through an evidence aggregation platform.

Read More

Topics: Drug Safety, Pharmacovigiance 2.0

Make Hair Great Again - The Real Reason for FDA Reform

Posted by Brian Overstreet on March 3, 2017

A personal note:  About a month ago, we published a blog post titled Drug Safety Progressives.  While 99.9% of the readers understood that this wasn’t a political statement, we did get hit with some great trolling that accused us of, among other things, pushing “Alt-Left Propaganda on a Left Wing Socialist website.”  How or why someone reached that conclusion is beyond me.  Regardless, I’m dedicating today’s blog post to those 0.1% of our readers who troll for an internet fight.  I’m confident that the rest of you will enjoy it too.

We know that with the fake news circulating these days, you may have missed the most important breaking story concerning President Trump in February.  That’s right, he’s taking something to maintain that famous hair – Propecia.

Read More

Topics: Drug Safety, FDA

Drug Safety Progressives – The Rise of the Pharmacovigilante

Posted by Jim Davis on February 2, 2017

The United States is a polarized place right now. Democrats vs. Republicans. Liberals vs. Conservatives. President Trump vs. the world. The divide runs deep and battle lines have been drawn. And while there is no escaping this highly publicized political chasm, there is another fight being played out in the shadows… The Drug Safety Progressives vs. the Drug Safety Conservatives.

I was at the DIA Pharmacovigilance and Risk Management conference last week, fittingly taking place in Washington D.C right after the inauguration and the women’s march.  The division was obvious.

Read More

Topics: Drug Safety, DIA

Advera Health Partners with APCER Life Sciences to Connect Drug Safety to Health Outcomes

Posted by Brian Overstreet on January 26, 2017

We were very excited this Monday to announce a new partnership with APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services to the pharmaceutical industry.  Working with the dedicated professionals at APCER will enable us to expand our reach into the safety and pharmacovigilance departments at pharmaceutical companies globally. 

Read More

Topics: Drug Safety, Health Outcomes

Real-Time Drug Safety Analysis with Evidex Alerts

Posted by Bob Kyle on January 20, 2017

This week we launched Evidex Alerts, a new feature that provides our clients with real-time updates on the latest impactful drug safety news. This is a project that our development and analyst teams have worked on diligently for the last three months, and I am excited to announce that it became a reality this week. 

Read More

Topics: Drug Safety, Clinical Trials, Evidex

Will 2017 Be The Year of Drug Safety?

Posted by Brian Overstreet on January 12, 2017

On this past Sunday’s 60 Minutes, astronomer Mike Brown made a bold prediction – that within three years the scientific community would identity a new, large 9th planet located in the outermost area of our solar system.  Even more astonishing was how certain he was about that prediction, “I would say at this point, I am certain….that’s a rare thing to say – for a prediction for a scientist.  And I’m willing to say it.”  Mike Brown has some credibility in this area, as he’s the guy who figured out that Pluto wasn’t a planet after all.  Maybe it’s his own guilt over breaking every school-kid’s heart that’s driving his prediction, but both his prediction and his certainty really fascinated me.  If you haven’t watched the report, I’d urge you to do so (link is here).

Read More

Topics: Drug Safety

Working Toward a Cure: The Foundation for Sarcoidosis Research

Posted by Jim Davis on January 5, 2017

In November 2016, I was honored to be asked to join the Board of Directors of the Foundation for Sarcoidosis Research (FSR). The foundation began in 1999 as a grassroots organization, and now has expanded their efforts and impact to become the leader in supporting sarcoidosis research. I'm looking forward to using my experiences both as a sarcoidosis patient and in drug safety to contribute to the mission. Please visit www.stopsarcoidosis.org for more information. 

I originally wrote the post below for the FSR blog. The original can be seen here

Read More

Topics: Drug Safety, sarcoidoisis

Looking Ahead - Drug Safety in 2017

Posted by Brian Overstreet on December 16, 2016

As 2016 winds down, am I the only one who feels exhausted? 

Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.

Read More

Topics: Drug Safety, Clinical Evidence, Evidex

Establish Drug Safety Benchmarks with an Evidence Aggregation Platform

Posted by Jim Davis on October 27, 2016

 


Drug safety is often equated with post-marketing pharmacovigilance, something that is required by manufacturers only after their drug is approved. But when drug safety data are presented in an evidence aggregation platform there are very strong use cases in pharmaceutical competitive intelligence, health economics and outcomes (HEOR), and R&D. An evidence aggregation platform takes multiple sources of information and boils it down into actionable insight. That insight often has use cases that span all departments and can meet the demands of various priorities. 

Read More

Topics: Drug Safety, Evidex, benchmarks, real world data, evidence aggregation platform, clinical trial results, adverse events

Subscribe to Email Updates